Alpha 2.0
Login Register
» Authors » Antoine Bougouin

Antoine Bougouin

Explore the profile of Antoine Bougouin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 1578
Followers 0
Related Specialties
Oncology
Allergy & Immunology
Molecular Biology
Top 10 Co-Authors
Catherine Sautes-Fridman
Wolf H Fridman
Guillaume Lacroix
Maxime Meylan
Antoine Italiano
Maud Toulmonde
Alban Bessede
Arnaud Mejean
Virginie Verkarre
Cheng-Ming Sun
Published In
Clin Cancer Res
Nature
Nat Cancer
Lancet Oncol
Lab Invest
Affiliations
Soon will be listed here.
Recent Articles
1.
Timing and location dictate monocyte fate and their transition to tumor-associated macrophages
Dunsmore G, Guo W, Li Z, Bejarano D, Pai R, Yang K, et al.
Sci Immunol . 2024 Jul; 9(97):eadk3981. PMID: 39058763
Tumor-associated macrophages (TAMs) are a heterogeneous population of cells whose phenotypes and functions are shaped by factors that are incompletely understood. Herein, we asked when and where TAMs arise from...
2.
Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study
Sun C, Toulmonde M, Spalato-Ceruso M, Peyraud F, Bessede A, Kind M, et al.
Mol Cancer . 2024 Feb; 23(1):37. PMID: 38374062
Soft tissue sarcomas (STS) are diverse mesenchymal tumors with few therapeutic options in advanced stages. Trabectedin has global approval for treating STS patients resistant to anthracycline-based regimens. Recent pre-clinical data...
3.
Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in Cancers
Vanhersecke L, Bougouin A, Crombe A, Brunet M, Sofeu C, Parrens M, et al.
Lab Invest . 2023 Feb; 103(5):100063. PMID: 36801637
Mature tertiary lymphoid structures (mTLSs) are organized lymphoid structures containing B lymphocytes admixed to CD23+ follicular dendritic cells. Their presence has been linked to improved survival and sensitivity to immune...
4.
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study
Carril-Ajuria L, Desnoyer A, Meylan M, Dalban C, Naigeon M, Cassard L, et al.
J Immunother Cancer . 2022 May; 10(5). PMID: 35640928
Background: The phase II NIVOREN GETUG-AFU 26 study reported safety and efficacy of nivolumab in patients with metastatic clear cell renal cell carcinoma (m-ccRCC) in a 'real-world setting'. We conducted...
5.
Pleiotropic Roles of Scavenger Receptors in Circadian Retinal Phagocytosis: A New Function for Lysosomal SR-B2/LIMP-2 at the RPE Cell Surface
Rieu Q, Bougouin A, Zagar Y, Chatagnon J, Hamieh A, Enderlin J, et al.
Int J Mol Sci . 2022 Apr; 23(7). PMID: 35408805
The retinal phagocytic machinery resembles the one used by macrophages to clear apoptotic cells. However, in the retina, the permanent contact between photoreceptor outer segments (POS) and retinal pigment epithelial...
6.
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
Vano Y, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, et al.
Lancet Oncol . 2022 Apr; 23(5):612-624. PMID: 35390339
Background: We previously reported a 35-gene expression classifier identifying four clear-cell renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments and sensitivities to sunitinib in metastatic clear-cell renal...
7.
Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors
Gantzer J, Davidson G, Vokshi B, Weingertner N, Bougouin A, Moreira M, et al.
Oncologist . 2022 Mar; 27(6):501-511. PMID: 35278076
Background: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are aggressive neoplasms. Data linking BAF alterations with tumor microenvironment (TME) and efficacy of immune checkpoint inhibitors (ICI) are contradictory. The TME of SMARCA4-UT...
8.
Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer
Meylan M, Petitprez F, Becht E, Bougouin A, Pupier G, Calvez A, et al.
Immunity . 2022 Mar; 55(3):527-541.e5. PMID: 35231421
The presence of intratumoral tertiary lymphoid structures (TLS) is associated with positive clinical outcomes and responses to immunotherapy in cancer. Here, we used spatial transcriptomics to examine the nature of...
9.
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
Vanhersecke L, Brunet M, Guegan J, Rey C, Bougouin A, Cousin S, et al.
Nat Cancer . 2022 Feb; 2(8):794-802. PMID: 35118423
Only a minority of patients derive long-term clinical benefit from anti-PD1/PD-L1 monoclonal antibodies. The presence of tertiary lymphoid structures (TLS) has been associated with improved survival in several tumor types....
10.
Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade
Terry S, Dalban C, Rioux-Leclercq N, Adam J, Meylan M, Buart S, et al.
Clin Cancer Res . 2021 Aug; 27(24):6749-6760. PMID: 34407968
Purpose: A minority of patients currently respond to single-agent immune-checkpoint blockade (ICB), and strategies to increase response rates are urgently needed. AXL is a receptor tyrosine kinase commonly associated with...